In this webinar, you'll explore the impact of RSV on U.S. infants, examine key clinical studies on nirsevimab, and review global real-world data on its effectiveness. You'll also learn how to implement immunization strategies to reduce RSV lower respiratory tract infections (LRTI), with practical takeaways for improving coverage and reimbursement decisions.
AMCP Legislative & Regulatory Briefing — HHS Unveils the Maximum Fair Price for the First 10 Drugs Selected for Medicare Negotiation